We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Proteins Identified in Metastatic Kidney Cancer

By LabMedica International staff writers
Posted on 20 Dec 2012
A unique set of proteins have been analyzed that are likely to be involved in the spread of metastatic renal cell carcinoma (RCC). More...


The discovery will help physicians recognize which tumors are going to behave more aggressively and provide those patients with more intensive treatment and closer follow-up.

Scientists collaborating with pathologists at St. Michael's Hospital (Toronto, ON, Canada) used differential proteomics with isobaric tags for relative and absolute quantitation (iTRAQ) labeling and liquid chromatography and mass spectrometry (LC-MS/MS) analysis to identify proteins that are differentially expressed in metastatic compared to primary RCC. Primary RCC tissues and matched normal kidney tissues from the same patient were obtained from nephrectomy specimens at the hospital and processed.

Western blot analysis, tissue microarray construction and immunohistochemistry were also performed. The team identified 29 proteins that change when cancer cells spread from the original site of the kidney tumor and all 29 proteins have been previously been linked to other malignancies. Of these, 12 were overexpressed (iTRAQ ratios of equal or greater than 1.5) and 17 were under expressed (iTRAQ ratios of equal to or less than 0.67).

The authors concluded that through quantitative proteomic analysis, they had identified differential protein expressions that can distinguish between aggressive and nonaggressive RCC tumors. Many of these proteins are involved in biological pathways pertinent to tumor progression and metastasis. In addition, their preliminary analysis showed that some of these dysregulated proteins may be useful clinical markers and validation of these markers would greatly improve RCC patient treatment and increase overall survival.

George M. Yousef, MD, PhD, the senior author of the study, said “Metastatic renal cell carcinoma is one of the most treatment-resistant malignancies and patients have dismal prognosis. Identification of markers that can predict the potential of metastases will have a great impact on improvement patient outcomes." The study was published on October 17, 2012, in the journal Molecular & Cellular Proteomics.

Related Links:

St. Michael's Hospital




New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Serological Pipet Controller
PIPETBOY GENIUS
New
Clinical Chemistry System
P780
New
Gold Member
Radial Immunodiffusion Assay
Radial Immunodifusion - C3 ID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.